Nelly G. Adel

2.0k total citations · 1 hit paper
27 papers, 1.4k citations indexed

About

Nelly G. Adel is a scholar working on Oncology, Hematology and Epidemiology. According to data from OpenAlex, Nelly G. Adel has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Hematology and 5 papers in Epidemiology. Recurrent topics in Nelly G. Adel's work include Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Nelly G. Adel is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Nelly G. Adel collaborates with scholars based in United States and Indonesia. Nelly G. Adel's co-authors include Paul B. Chapman, Troy Z. Horvat, Michael A. Postow, Mark A. Dickson, Parisa Momtaz, Richard D. Carvajal, Katherine S. Panageas, Kaitlin M. Woo, Margaret K. Callahan and Jedd D. Wolchok and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biology of Blood and Marrow Transplantation.

In The Last Decade

Nelly G. Adel

25 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

2015 808 citations Troy Z. Horvat, Nelly G. Adel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nelly G. Adel United States	9	926	245	229	223	193	27	1.4k
Ho‐Young Yhim South Korea	17	361 0.4×	128 0.5×	167 0.7×	244 1.1×	156 0.8×	116	1.2k
Sung Hwa Bae South Korea	19	468 0.5×	197 0.8×	192 0.8×	103 0.5×	61 0.3×	101	1.2k
Yeung‐Chul Mun South Korea	22	647 0.7×	237 1.0×	231 1.0×	125 0.6×	92 0.5×	149	1.8k
Renate Thalhammer Austria	14	405 0.4×	84 0.3×	133 0.6×	131 0.6×	196 1.0×	35	1.0k
Ute Klinkhardt Germany	19	289 0.3×	185 0.8×	124 0.5×	202 0.9×	459 2.4×	42	1.2k
Emanuele Naglieri Italy	15	336 0.4×	200 0.8×	89 0.4×	206 0.9×	107 0.6×	42	1.0k
Herbert Stöger Austria	19	562 0.6×	259 1.1×	252 1.1×	61 0.3×	80 0.4×	68	1.1k
Sung‐Hyun Kim South Korea	17	371 0.4×	223 0.9×	66 0.3×	117 0.5×	73 0.4×	105	1.0k
Abdurrahman Işıkdoğan Türkiye	19	537 0.6×	424 1.7×	54 0.2×	60 0.3×	82 0.4×	146	1.2k
Kyoung Ha Kim South Korea	17	325 0.4×	240 1.0×	65 0.3×	78 0.3×	45 0.2×	72	932

Countries citing papers authored by Nelly G. Adel

Since Specialization

Citations

This map shows the geographic impact of Nelly G. Adel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nelly G. Adel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nelly G. Adel more than expected).

Fields of papers citing papers by Nelly G. Adel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nelly G. Adel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nelly G. Adel. The network helps show where Nelly G. Adel may publish in the future.

Co-authorship network of co-authors of Nelly G. Adel

This figure shows the co-authorship network connecting the top 25 collaborators of Nelly G. Adel. A scholar is included among the top collaborators of Nelly G. Adel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nelly G. Adel. Nelly G. Adel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adel, Nelly G.. (2019). Current treatment landscape and emerging therapies for pancreatic cancer.. PubMed. 25(1 Suppl). S3–S10. 22 indexed citations

Seddon, Amanda N., Joshua Chaim, Oğuz Akın, et al.. (2018). Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. Leukemia Research. 68. 48–50. 3 indexed citations

Buie, Larry W., et al.. (2016). Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Annals of Hematology. 95(12). 2009–2015. 47 indexed citations

Lin, Andrew, et al.. (2016). Outcomes of Rituximab for EBV Viremia/Post-Transplant Lymphoproliferative Disease in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 128(22). 4623–4623. 3 indexed citations

Devlin, Sean M., Nelly G. Adel, Heather Landau, et al.. (2016). Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. Leukemia & lymphoma. 58(5). 1123–1129. 12 indexed citations

Peterson, Tim, Andrew Lin, Patrick Hilden, et al.. (2015). Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 1290–1290.

Harnicar, Stephen, Doris M. Ponce, Patrick Hilden, et al.. (2015). Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 21(5). 920–925. 24 indexed citations

Shoushtari, Alexander N., et al.. (2015). Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events.. Journal of Clinical Oncology. 33(15_suppl). e20023–e20023. 5 indexed citations

Buie, Larry W., et al.. (2015). Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate. Blood. 126(23). 3711–3711. 1 indexed citations

10.

Horvat, Troy Z., Nelly G. Adel, Parisa Momtaz, et al.. (2015). Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology. 33(28). 3193–3198. 808 indexed citations breakdown →

11.

Harnicar, Stephen, Doris M. Ponce, Junting Zheng, et al.. (2014). Higher Mycophenolic Acid (MPA) Trough Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients. Biology of Blood and Marrow Transplantation. 20(2). S52–S53. 1 indexed citations

12.

Adel, Nelly G., Sean M. Devlin, Heather Landau, et al.. (2014). Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. Blood. 124(21). 848–848.

13.

Hilden, Patrick, Sean M. Devlin, Raajit K. Rampal, et al.. (2013). High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy. Blood. 122(21). 2695–2695. 1 indexed citations

14.

Harnicar, Stephen, Doris M. Ponce, Junting Zheng, et al.. (2013). Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. Blood. 122(21). 3297–3297. 1 indexed citations

15.

Adel, Nelly G., et al.. (2012). Cryotherapy Reduces Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation. Blood. 120(21). 4265–4265. 1 indexed citations

16.

Lowery, Maeve A., Kenneth H. Yu, Nelly G. Adel, et al.. (2012). Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC).. Journal of Clinical Oncology. 30(15_suppl). 4057–4057. 12 indexed citations

17.

Adel, Nelly G., et al.. (2012). Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience.. Journal of Clinical Oncology. 30(4_suppl). 294–294. 1 indexed citations

18.

Ganetsky, Alex, Nelly G. Adel, Richard Kinh Gian, & Diane Reidy‐Lagunes. (2012). The efficacy of capecitabine and temozolomide for the treatment of metastatic neuroendocrine tumors: Memorial Sloan-Kettering Cancer Center experience.. Journal of Clinical Oncology. 30(4_suppl). 363–363. 6 indexed citations

19.

Adel, Nelly G., Emily McCullagh, Lilian Reich, et al.. (2011). Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),. Blood. 118(21). 4059–4059. 3 indexed citations

20.

Harnicar, Stephen, Nelly G. Adel, & Joseph G. Jurcic. (2009). Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. Journal of Oncology Pharmacy Practice. 15(3). 175–182. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact